InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR - Free Report) in a research report released on Wednesday morning. The firm issued a sell rating on the stock.

Separately, Lake Street Capital began coverage on shares of InspireMD in a research note on Wednesday, December 11th. They set a "buy" rating and a $5.00 price target on the stock.

InspireMD Stock Performance

NSPR traded down $0.12 during midday trading on Wednesday, reaching $2.43. The company had a trading volume of 53,118 shares, compared to its average volume of 29,987. The business has a 50-day moving average price of $2.84 and a two-hundred day moving average price of $2.73. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.42. The stock has a market cap of $63.37 million, a PE ratio of -3.24 and a beta of 0.99.

InspireMD (NYSE:NSPR - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.04. The business had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same period in the prior year, the company earned ($0.15) earnings per share. On average, research analysts anticipate that InspireMD will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On InspireMD

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Legato Capital Management LLC purchased a new stake in InspireMD in the fourth quarter valued at approximately $47,000. Affiance Financial LLC grew its position in InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company's stock worth $497,000 after acquiring an additional 5,376 shares in the last quarter. Finally, Parkman Healthcare Partners LLC bought a new position in InspireMD in the third quarter valued at $279,000. Hedge funds and other institutional investors own 44.78% of the company's stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.